H CYTE (QB) Stock Price - HCYT

0.0142 (23.28%)
Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
H CYTE Inc (QB) HCYT OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.0142 23.28% 0.0752 0.061 0.08 0.061 0.061 16:21:06
Bid Price Ask Price Spread Spread % News
0.06 0.0999 0.0399 39.94% 1 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
18 134,350 $ 0.068277 $ 9,173 54,971 0.052 - 0.625
Last Trade Time Type Quantity Stock Price Currency
15:51:05 200 $ 0.0752 USD

H CYTE (QB) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 7.50M 99.77M - - 18.28M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
5.21k $ - 0.00% - -

more financials information »

H CYTE (QB) News

Loading Messages....

Latest HCYT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HCYT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.100.13150.0520.0714713135,201-0.0248-24.8%
1 Month0.19550.19550.0520.100598580,218-0.1203-61.53%
3 Months0.11010.19550.0520.12159354,920-0.0349-31.7%
6 Months0.16050.2990.0520.132519258,958-0.0853-53.15%
1 Year0.500.6250.0520.17479752,286-0.4248-84.96%
3 Years0.500.6250.0520.17479752,286-0.4248-84.96%
5 Years0.500.6250.0520.17479752,286-0.4248-84.96%

H CYTE (QB) Description

Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX System, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. On October 18, 2018, MedoveX entered into an Asset Purchase Agreement with Regenerative Medicine Solutions, LLC, Lung Institute LLC ("LI"), RMS Lung Institute Management LLC ("RMS LI Management") and Cognitive Health Institute Tampa, LLC ("CHIT"),(collectively"RMS"). On January 8, 2019, the Asset Purchase Agreement was amended and the Company acquired certain assets and assumed certain liabilities of RMS. RMS was incorporated in Delaware on December 26, 2012. RMS is a healthcare medical biosciences company that develops and implements advance innovative treatment options in regenerative medicine to treat an array of debilitating medical conditions. In addition, the company is the operator and manager of the various Lung Health Institute clinics in Tampa, Nashville, Scottsdale, Pittsburgh, and Dallas To learn more about Medovex Corp., visit www.medovex.com.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.